欢迎收听今日医学前沿!在最新的癌症治疗综述中,一项系统性回顾和元分析显示,Trastuzumab deruxtecan(T-DXd)在HER2阳性乳腺癌患者中展现出显著的治疗效果,特别是在脑转移和脑膜疾病。研究涵盖了18项研究,786名患者,结果显示60.4%的客观反应率、94.4%的疾病控制率和79.3%的临床获益率,以及12个月无进展生存率和总生存率分别为64.7%和82.7%。这为HER2阳性乳腺癌患者的中枢神经系统转移提供了新的治疗希望。不要错过这一突破性进展,深入了解T-DXd如何改变HER2阳性乳腺癌治疗的未来!
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare
The method of invention, AI's new clock speed and why capital markets are confused
05 Dec 2025
Azeem Azhar's Exponential View